In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant < b > < i > Pseudomonas aeruginosa < /i > < /b >

This study evaluated the antimicrobial activities of various combination therapies againstP. aeruginosa with high antimicrobial resistance, including multidrug-resistantP. aeruginosa (MDRP) using an in vitro and in vivo study.Methods: We evaluated 24 combination therapies, including colistin, aztreonam, meropenem, ceftazidime, ciprofloxacin, amikacin, rifampicin, arbekacin and piperacillin against 15 MDRP isolates detected at Aichi Medical University Hospital with the break-point checkerboard method. Based on the results of the in vitro study, we evaluated antimicrobial activity against highly antimicrobial-resistantP. aeruginosa with an in vivo murine thigh infection model.Results: The combination regimens including colistin and aztreonam showed higher antimicrobial activity against the 15 MDRP isolates. In the in vivo study, the high-dose colistin monotherapy (16 mg/kg every 12 h) achieved greater log10 CFU changes than the normal-dose colistin regimen (8 mg/kg every 12 h) against 5P. aeruginosa isolates, including 2 MDRP isolates (p
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research